Growth factor receptor inhibitor

Growth factor receptor inhibitors (growth factor inhibitors, growth factor receptor blockers, growth factor blockers, growth factor receptor antagonists, growth factor antagonists) are drugs that target the growth factor receptors of cells. They interfere with binding of the growth factor to the corresponding growth factor receptors, impeding cell growth and are used medically to treat cancer.[1][2]

Drugs of this type include those that target the epidermal growth factor receptors of epidermal cells (EGFR inhibitors)[3] and those that target vascular endothelial growth factor receptors (VEGFR inhibitors).[4]

Growth factor receptor inhibitors in cancer treatment and research

In cancer treatment, growth factor receptor inhibitors have been used to target cancer cells.[2]

In cancer research, growth factor receptor inhibitors have been applied to protect normal cells selectively from the toxic side-effects of chemotherapy targeted against cancer cells.[5]

References

  1. ↑ Cancer growth blockers, Cancer Research UK
  2. 1 2 Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, Journal of Clinical Oncology.
  3. ↑ Kris, Mark G. (2003). "Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer<SUBTITLE>A Randomized Trial</SUBTITLE>". JAMA 290 (16): 2149–58. doi:10.1001/jama.290.16.2149. ISSN 0098-7484. PMID 14570950.
  4. ↑ Strumberg, D. (2004). "Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors". Journal of Clinical Oncology 23 (5): 965–972. doi:10.1200/JCO.2005.06.124. ISSN 0732-183X.
  5. ↑ Blagosklonny, Mikhail; Pardee (June 1, 2001). "Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells". Cancer Research 61: 4310.

Further reading

External links

This article is issued from Wikipedia - version of the Sunday, January 18, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.